ArticleFrontiers in systems biology2026
Bidirectional network hubs: NT-genes as candidate targets for partial cancer reversal.
Article in Frontiers in systems biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- N-Gene and T-Gene deregulation networks: a data-driven causal framework for the analysis of gene interventions in cancer.Frontiers in systems biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Reversing the tumor phenotype is a long-standing challenge in cancer biology. Although GRNs comprise thousands of genes, normal and tumor tissues occupy distinct, low-dimensional attractors in expression space, raising the possibility that targeting a few key genes could induce widespread transcriptional changes. We build on two previously developed concepts: 1) N- and T-markers (genes with exclusive expression intervals in normal or tumor samples, respectively), and 2) Gene Deregulation Networks (GDNs) - directed acyclic graphs inferred from expression data, in which a link from C to E indicates that a deregulation at C increases the probability of a deregulation at E. A subset of N and T-genes, namely, NT-markers, appear in both networks and may act as bridges for phenotype reversal. Methods: Using TCGA bulk RNA-Seq data from five cancer types we identified N-, T- and NT-genes based on statistically significant exclusive expression intervals. Discretized expression states (N-active, T-active, inactive) are then associated with normal-exclusive, tumor-exclusive and non-exclusive expression intervals. GDNs were constructed with the CChains algorithm using the Loevinger coefficient, followed by Reichenbach (common cause) and Mokken (transitivity) pruning. We introduced a quantitative model to predict intervention outcomes in a tumor using gene activation frequencies and two topological metrics: the composed coverage and the fraction of the T-network unreached by the reverse deactivation cascade (U). We also use a Glauber-like dynamical model to simulate interventions. Results: We predict that pure T-gene interventions mainly alter the T-network, while pure N-gene interventions create a mixed normal-tumor state. In contrast, high-frequency NT-genes are predicted to simultaneously deactivate T-cascades and reactivate N-programs. The unreached fraction U varies across cancers: for perfect diagnostic panels, U ≈ 30% in PRAD but only ≈6% in LUAD. Escape probability also depends on tumor stage and on the spontaneous activation rate. Conclusion: NT-genes with high dual frequency are predicted optimal targets for partial phenotype reversal. The combination of composed coverage, unreached fraction and normal-state relevance provides a quantitative guide for designing multi-target therapies. The framework is general and yields testable predictions for intervention outcomes across cancer types.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.